BioSpace News Archive

Business

Ablynx Announces Board Changes

Ablynx today announced that Dr Peter Fellner, who has served as Chairman since 2013, has decided to resign from the Board with immediate effect.

January 8, 2018
·
3 min read
Relevium Update On Shares-For-Services Agreement

he shares are subject to a four month hold period. Pricing was determined using the VWAP on the close of January 5, 2018, when submission to the TSX Venture Exchange approval was filed.

January 8, 2018
·
1 min read
Business

ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer technology

The targets that will be pursued in the collaboration and financial details about the collaboration are not disclosed.

January 8, 2018
·
4 min read
Business

Retrophin Provides Corporate Update and 2018 Outlook

Preliminary full-year 2017 revenue of approximately $155 million.

January 8, 2018
·
5 min read
Business

Integra LifeSciences Announces Preliminary Fourth Quarter 2017 Financial Result

The company expects reported revenue for the fourth quarter 2017 to be approximately $365 million, an increase of over 40% compared to $255.7 million for the fourth quarter of 2016.

January 8, 2018
·
7 min read
Biotech Bay

Dynavax Announces HEPLISAV-B is Now Available in the United States for the Prevention of Hepatitis B in Adults

HEPLISAV-B can now be ordered through a network of distributors, which will broaden over the next few weeks.

January 8, 2018
·
6 min read
Business

APEIRON and Evotec Achieve First Milestone in Immuno-Oncology Alliance With Sanofi

The milestone payment of € 3 million will be split equally between the two biotech companies.

January 8, 2018
·
5 min read
Business

Wright Medical Group N.V. Announces Preliminary Fourth Quarter and Full-Year 2017 Net Sales

The company expects net sales for the fourth quarter of 2017 to be approximately $217.6 million.

January 8, 2018
·
10 min read
Drug Development

Galapagos Release: Positive Topline Results With GLPG1972 in Osteoarthritis Patients

Galapagos evaluated GLPG1972 in a randomized, placebo-controlled, double-blind Phase 1b study in 30 patients aged 50 to 75 years with diagnosis of knee and/or hip osteoarthritis, in the United States.

January 8, 2018
·
5 min read
Business

DexCom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2017 and Provides Initial 2018 Outlook

DexCom today reported that it achieved preliminary, unaudited revenue of approximately $218 million for the fourth quarter ended December 31, 2017, an increase of 27% over the fourth quarter of 2016.

January 8, 2018
·
3 min read